Epoxy (EPXY) 10-Q/A 21 May 15 2014 Q2 Quarterly report (amended) Financial data

Document_and_Entity_Informatio

Document and Entity Information	6 Months Ended
	Jun. 30, 2014	Aug. 14, 2014
Document and Entity Information [Abstract]
Entity Registrant Name	Epoxy, Inc.
Entity Central Index Key	1428816
Amendment Flag	TRUE
Amendment Description	Amendment No. 1
Current Fiscal Year End Date	-19
Document Type	10-Q
Document Period End Date	30-Jun-14
Document Fiscal Year Focus	2014
Document Fiscal Period Focus	Q2
Entity Filer Category	Smaller Reporting Company
Entity Common Stock, Shares Outstanding		169,758,040

Consolidated_Balance_Sheets_Un

Consolidated Balance Sheets (Unaudited) (USD $)	Jun. 30, 2014	Dec. 31, 2013
Current
Cash	$544	$30,467
Accounts receivable	1,080	2,330
Total Current Assets	1,624	32,797
Trademark and Patent, net	7,695	7,695
Total Assets	9,319	40,492
Current
Accounts payable and accrued liabilities	88,117	64,401
Loan payable	63,085	63,573
Derivative liabilities	51,708	23,790
Total Current Liabilities	202,910	151,764
Convertible notes, net of unamortized discount	33,863	19,190
Total Liabilities	236,773	170,954
STOCKHOLDERS' DEFICIT
Common Stock, $0.00001 par value; authorized: 480,000,000 shares, 169,758,040 and 168,824,707 shares issued and outstanding as of June 30, 2014 and December 31, 2013, respectively	1,697	1,688
Additional Paid-in Capital	172,475	152,689
Accumulated deficit	-401,877	-285,090
Total Stockholders' Deficit	-227,454	-130,462
Total Liabilities and Stockholders' Deficit	9,319	40,492
Series A Preferred shares
STOCKHOLDERS' DEFICIT
Preferred Stock, $0.00001 par value:	251	251
Series B Preferred shares
STOCKHOLDERS' DEFICIT
Preferred Stock, $0.00001 par value:

Consolidated_Balance_Sheets_Un1

Consolidated Balance Sheets (Unaudited) (Parentheticals) (USD $)	Jun. 30, 2014	Dec. 31, 2013
Preferred stock par value (in Dollars per share)	$0.00	$0.00
Common stock par value (in Dollars per share)	$0.00	$0.00
Common stock, shares authorized	480,000,000	480,000,000
Common stock, shares issued	169,758,040	168,824,707
Common stock, shares outstanding	169,758,040	168,824,707
Preferred Class A
Preferred stock, shares authorized	35,000,000	35,000,000
Preferred stock, shares issued	25,080,985	25,080,985
Preferred stock, shares outstanding	25,080,985	25,080,985
Preferred Class B
Preferred stock, shares authorized	15,000,000	15,000,000
Preferred stock, shares issued
Preferred stock, shares outstanding

Consolidated_Statements_of_Ope

Consolidated Statements of Operations (Unaudited) (USD $)	3 Months Ended		6 Months Ended
	Jun. 30, 2014	Jun. 30, 2013	Jun. 30, 2014	Jun. 30, 2013
Income Statement [Abstract]
Revenue	$3,349	$2,916	$7,734	$5,290
Operating Expenses
Professional fees	19,128	522	27,964	828
Software development expenses	6,461	6,204	14,176	28,738
Consulting fee	14,973	6,058	22,955	10,448
General and administrative expenses	11,131	19,221	18,592	38,316
Total operating expenses	51,693	32,005	83,687	78,330
Loss from operations	-48,344	-29,089	-75,953	-73,040
Other Income (Expenses):
Loss on change in fair value of derivative liabilities	-19,701		-16,727
Interest expenses	-4,735		-9,435
Accretion of discount on convertible notes	-7,940		-14,672
Total other expenses	-32,376		-40,834
Net loss	($80,720)	($29,089)	($116,787)	($73,040)
Net loss per share - basic and diluted	$0	$0	$0	$0
Weighted average shares outstanding - basic and diluted	169,450,348	24,514,319	169,139,256	24,514,319

Consolidated_Statements_of_Cas

Consolidated Statements of Cash Flows (Unaudited) (USD $)	6 Months Ended
	Jun. 30, 2014	Jun. 30, 2013
Cash flows from Operating Activities
Net loss	($116,787)	($73,040)
Adjustments to reconcile net loss to net cash used in operations:
Amortization of trademark and patent		689
Loss on change in fair value of derivative liabilities	16,727
Accretion of discounts on convertible notes	14,672
Imputed interest	2,986
Foreign exchange in loan payable	-488
Changes in operating assets and liabilities:
Accounts receivables	1,250	-1,250
Accrued expenses	16,583
Accounts payable	7,134	-7,572
Net cash used in operating activities	-57,923	-81,173
Cash flows from Financing Activities
Proceeds from sale of common stock	28,000
Proceeds from loan payable		83,198
Net cash provided by financing activities	28,000	83,198
Increase (decrease) in cash during the period	-29,923	2,025
Cash, beginning of period	30,467	492
Cash, end of period	544	2,517
Cash paid for:
Interest	2,986
Income taxes
Non-Cash Transactions
Shares and warrants reclassified as derivative liability	$11,191

Description_of_Business_and_Ba

Description of Business and Basis of Presentation	6 Months Ended
	Jun. 30, 2014
Description of Business and Basis of Presentation [Abstract]
Description of business and basis of presentation	Note 1 – Description of business and basis of presentation
	Organization and nature of business
	Neohydro Technologies Corp. (the “Company”) was incorporated in the State of Nevada on November 13, 2007 as Rioridge Resources Corp. On July 22, 2008, the Company changed its name to Neohydro Technologies Corp.
	On August 1, 2014, the Company’s name changed from NeoHydro Technologies Corp. to Epoxy, Inc.  in regard to actions taken on May 23, 2014, when the Board of Directors of the Company (the “Board”) approved, and recommended to the Majority Stockholders that they approve the Name Change. On May 27, 2014, the Majority Stockholders approved the Name Change by written consent in lieu of a meeting, in accordance with Nevada law. On August 4, 2014, the Company submitted the Name Change to FINRA for their review and approval, as well as the approval of a symbol change from NHYT to EPXY.   The Company filed an amendment to our Articles of Incorporation with the Secretary of State of Nevada changing our name to Epoxy, Inc. effective on August 1, 2014.
	The Company, through its wholly owned subsidiary, Couponz, Inc.,  is the developer of Epoxy app, an application or "app" for iPhone iOS and Android operating systems. Epoxy is an innovative smart phone application designed and created to conveniently connect business owners and consumers in order to ease marketing frustrations. The mobile app gives loyal customers the ease of keeping track of rewards and punch cards all in one place while also giving opportunities to review and share businesses with friends. In turn, Epoxy provides businesses the ability to reward customers, share offers, and deliver information about special events with their customers.
	Financial Statements Presented
	The accompanying unaudited financial statements have been prepared in accordance with generally accepted accounting principles for interim financial information and with the instructions for Form 10-Q and Article 210 8-03 of Regulation S-X.  Accordingly, they do not include all of the information and footnotes required by generally accepted accounting principles for complete financial statements.  In the opinion of management, all adjustments considered necessary for a fair presentation have been included.  All such adjustments are of a normal recurring nature.  Operating results for the six month period ended June 30, 2014, are not necessarily indicative of the results that may be expected for the fiscal year ending December 31, 2014.  For further information refer to the financial statements and footnotes thereto included in the Company’s Annual Report on Form 10-K for the fiscal year ended December 31, 2013 as filed with the Securities and Exchange Commission on April 15, 2014.
	Certain reclassifications have been made to the prior period’s financial statements to conform to the current period’s presentation.

Going_Concern

Going Concern	6 Months Ended
	Jun. 30, 2014
Going Concern [Abstract]
Going Concern	Note 2 – Going Concern
	At June 30, 2014 and 2013, the Company had net losses of $116,787 and $73,040, respectively. The Company believes that its existing capital resources may not be adequate to enable it to execute its business plan. These conditions raise substantial doubt as to the Company’s ability to continue as a going concern. The Company estimates that it will require additional cash resources during 2014 based on its current operating plan and condition. The Company expects cash flows from operating activities to improve, primarily as a result of an increase in revenue and a decrease in certain operating expenses, although there can be no assurance thereof. The accompanying consolidated financial statements do not include any adjustments that might be necessary should we be unable to continue as a going concern. If we fail to generate positive cash flow or obtain additional financing, when required, we may have to modify, delay, or abandon some or all of our business and expansion plans.

Correction_of_an_Error

Correction of an Error	6 Months Ended
	Jun. 30, 2014
Correction of an Error [Abstract]
Correction of an error	Note 3 – Correction of an error
	During the preparation of the quarterly report for the period ended March 31, 2014, the Company discovered an immaterial error related to its December 31, 2013 balance sheet. The error related to the valuation of an embedded derivative liability, in which the derivative liability was calculated using the wrong number of shares exceeding our authorized (see Note 7). The resulting error totaled $13,824. Pursuant to the Securities and Exchange Commission’s SAB Topic 108, the company has corrected this error in the accompanying December 31, 2013 balance sheet.
	The following table reflects the amounts originally reported and as adjusted for each major caption of the balance sheet:
		31-Dec-13			31-Dec-13
		(As Adjusted)			(Original)
	Consolidated Balance Sheets:
	Derivative liabilities	$	23,790		$	37,614
	Total Liabilities	$	170,954		$	184,778
	Additional paid in capital	$	152,689		$	138,865
	Total stockholders' deficit	$	(130,462	)	$	(144,286	)
	Total liabilities and stockholders' deficit	$	40,492		$	40,492

Fair_Value_Measurements

Fair Value Measurements	6 Months Ended
	Jun. 30, 2014
Fair Value Measurements [Abstract]
Fair Value Measurements	Note 4- Fair Value Measurements
	FASB ASC 820, Fair Value Measurements and Disclosures, defines fair value as the exchange price that would be received for an asset or paid to transfer a liability (an exit price) in the principal or most advantageous market for the asset or liability in an orderly transaction between market participants on the measurement date. FASB ASC 820 also establishes a fair value hierarchy which requires an entity to maximize the use of observable inputs and minimize the use of unobservable inputs when measuring fair value. FASB ASC 820 describes three levels of inputs that may be used to measure fair value:
	Level 1 – Quoted prices in active markets for identical assets or liabilities.
	Level 2 – Observable inputs other than Level 1 prices, such as quoted prices for similar assets or liabilities; or other inputs that are observable or can be corroborated by observable market data for substantially the full term of the assets or liabilities.
	Level 3 – Unobservable inputs that are supported by little or no market activity and that are financial instruments whose values are determined using pricing models, discounted cash flow methodologies, or similar techniques, as well as instruments for which the determination of fair value requires significant judgment or estimation.
	If the inputs used to measure the financial assets and liabilities fall within more than one level described above, the categorization is based on the lowest level of input that is significant to the fair value measurement of the instrument.
	The following table provides a summary of the fair value of our derivative liabilities as of June 30, 2014 and December 31, 2013:
		Fair value measurements
		on a recurring basis
		Level 1		Level 2		Level 3
	As of June 30, 2014:
	Liabilities
	Embedded derivative	$	-	$	-	$	51,708
	As of December 31, 2013:
	Liabilities
	Embedded derivative	$	-	$	-	$	23,790

Loans_Payable

Loans Payable	6 Months Ended
	Jun. 30, 2014
Loans Payable and Convertible Notes [Abstract]
Loans Payable	Note 5- Loans Payable
	At June 30, 2014, the Company is indebted to unrelated third parties for $63,085 (December 31, 2013 - $63,573). The loan is non-interest bearing and is due on demand. During the six months ended June 30, 2014, the Company recorded imputed interest of $2,986.

Convertible_Notes

Convertible Notes	6 Months Ended
	Jun. 30, 2014
Loans Payable and Convertible Notes [Abstract]
Convertible Notes	Note 6- Convertible Notes
	a)	On November 27, 2012, the Company entered into a convertible loan agreement. The Company received $25,000 which bears interest at 10% per annum and is due on November 27, 2015. Interest shall accrue from the advancement date and shall be payable quarterly. Any portion of the loan and unpaid interest are convertible at any time at the option of the lender into shares of common stock of the Company at a conversion price of $0.0005 per share. The Company recognized the intrinsic value of the embedded beneficial conversion feature of $25,000 as additional paid-in capital and reduced the carrying value of the convertible debenture to $nil. The carrying value will be accreted over the term of the convertible debenture up to its face value of $25,000. At June 30, 2014, the carrying values of the convertible debenture and accrued convertible interest thereon were $7,057 and $3,973, respectively.
	b)	On November 27, 2012, the Company entered into a convertible loan agreement. The Company received $25,000 which bears interest at 10% per annum and is due on November 27, 2015. Interest shall accrue from the advancement date and shall be payable quarterly. Any portion of the loan and unpaid interest are convertible at any time at the option of the lender into shares of common stock of the Company at a conversion price of $0.0005 per share. The Company recognized the intrinsic value of the embedded beneficial conversion feature of $25,000 as additional paid-in capital and reduced the carrying value of the convertible debenture to $nil. The carrying value will be accreted over the term of the convertible debenture up to its face value of $25,000. As at June 30, 2014, the carrying values of the convertible debenture and accrued convertible interest thereon were $7,057 and $3,973, respectively.
	c)	On November 27, 2012, the Company entered into a convertible loan agreement. The Company received $40,000 which bears interest at 10% per annum and is due on November 27, 2015. Interest shall accrue from the advancement date and shall be payable quarterly. Any portion of the loan and unpaid interest are convertible at any time at the option of the lender into shares of common stock of the Company at a conversion price of $0.0005 per share. The Company recognized the intrinsic value of the embedded beneficial conversion feature of $40,000 as additional paid-in capital and reduced the carrying value of the convertible debenture to $nil. The carrying value will be accreted over the term of the convertible debenture up to its face value of $40,000. As at June 30, 2014, the carrying values of the convertible debenture and accrued convertible interest thereon were $11,292 and $5,337, respectively.
	d)	On November 27, 2012, the Company entered into a convertible loan agreement. The Company received $35,000 which bears interest at 10% per annum and is due on November 27, 2015. Interest shall accrue from the advancement date and shall be payable quarterly. Any portion of the loan and unpaid interest are convertible at any time at the option of the lender into shares of common stock of the Company at a conversion price of $0.0005 per share. The Company recognized the intrinsic value of the embedded beneficial conversion feature of $35,000 as additional paid-in capital and reduced the carrying value of the convertible debenture to $nil. The carrying value will be accreted over the term of the convertible debenture up to its face value of $35,000. As at June 30, 2014, the carrying values of the convertible debenture and accrued convertible interest thereon were $8,457 and $5,562, respectively.
	The Company analyzed the conversion feature of above Convertible Notes for derivative accounting consideration under FASB ASC 470 and determined that the conversion feature did not create embedded derivatives.

Common_Stock

Common Stock	6 Months Ended
	Jun. 30, 2014
Common Stock [Abstract]
Common stock	Note 7 – Common stock
	On April 30, 2014, the Company the Company received the final $28,000 installment in respect of a funding agreement entered into on June 17, 2013 (ref: Note 10) for a total of $100,000.  The Company accepted a subscription for 933,333 shares of common stock at $0.03 per share for cash proceeds of $28,000 and the Company also agreed to issue a 2-year warrant entitling the holder to acquire an additional 93,333 and shares of common stock at an exercise price of $0.30 per share.

Share_Purchase_Warrants

Share Purchase Warrants	6 Months Ended
	Jun. 30, 2014
Share Purchase Warrants [Abstract]
Share Purchase Warrants	Note 8 - Share Purchase Warrants
	During the six month period ended June 30, 2014 the Company issued a 2-year warrant entitling the holders to acquire an additional 93,333 shares of common stock at an exercise price of $0.30 per share as part of Funding Agreement described below in Note 10.
	As June 30, 2014, the following share purchase warrants were outstanding:
		Warrants		Weighted Average Exercise Price
	Outstanding - December 31, 2013		856,667		0.12
	Granted		93,333		0.3
	Forfeited/Canceled		-		-
	Exercised		-		-
	Outstanding – June 30, 2014		950,000		0.14
	Exercisable – June 30, 2014		950,000		0.14
	The intrinsic value of these warrants was $0 at June 30, 2014.

Derivative_Liabilities

Derivative Liabilities	6 Months Ended
	Jun. 30, 2014
Derivative Liabilities [Abstract]
Derivative Liabilities	Note 9- Derivative Liabilities
	As of June 30, 2014, we have determined that we currently have (i) the following shares of common stock issued, and (ii) outstanding instruments which are convertible into the shares of common stock indicated below in connection with warrants, convertible notes and preferred shares previously issued by the Company or agreements with the Company:
		169,758,040		Common Stock Issued and Outstanding
		950,000		Common Shares exercised from warrants (950,000 warrants outstanding)
		250,000,000		Common Shares convertible from convertible notes ($125,000 converted at $0.0005 per share )
		62,702,463		Common Shares convertible from Preferred Series A (25,080,985 shares outstanding)
		1,333,333		Common Shares convertible from Preferred Series A warrants (533,333 warrants outstanding)
		484,743,836		Total Common Shares Outstanding and Accounted For/Reserved
	Accordingly, given the fact that the Company currently has 480,000,000 shares of common stock authorized, the Company could exceed its authorized shares of common stock by approximately 4,743,836 shares (December 31, 2013 – 3,717,168 shares) if all of the financial instruments described in the table above were exercised or converted into shares of common stock. At June 30, 2014, 4,743,836 of these shares were in excess of the authorized shares and were accounted for as a derivative liability. The fair value of these 4,743,836 common shares was determined to be $51,708 ($23,790 as to 3,717,168 shares as of December 31, 2013) using the closing price of Epoxy’s common stock.
			Exceed number of authorized shares		Derivate Liabilities
	Balance, December 31, 2013			3,717,169	$	23,790
	Add:  Common shares issued			933,334		10,174
	Common shares for exercise underlying warrants			93,333		1,017
	Change in fair value of derivative liabilities			-		16,727
	Balance: June 30, 2014			4,743,836	$	51,708
	We have evaluated our convertible cumulative preferred stock under the guidance set out in FASB ASC 470-20 and have accordingly classified these shares as equity in the consolidated balance sheets.

Commitments

Commitments	6 Months Ended
	Jun. 30, 2014
Commitments [Abstract]
Commitments	Note 10 - Commitments
	On June 17, 2013, the Company entered into a Funding Agreement whereby an investor agreed to purchase $100,000 worth of shares of common stock of the Company at $0.03 per share within 90 days (which may be extended by consent of both parties to 120 days) and receive a 2-year warrant for an additional $100,000 worth of shares at $0.30 per share. As of June 30, 2014, the Company has received a total of $100,000 under the Funding Agreement towards the committed purchase value, but not yet issued the shares.
	On July 16, 2013 the Company entered into a second Funding Agreement whereby an investor agreed to purchase $17,000 worth of shares of common stock of the Company at $0.03 per share and receive a 2-year warrant for an additional $17,000 worth of shares at $0.03 per share. As of June 30, 2014, the Company had received $17,000 under the Funding Agreement but has not yet issued the shares.

Subsequent_Events

Subsequent Events	6 Months Ended
	Jun. 30, 2014
Subsequent Events [Abstract]
Subsequent events	Note 11 – Subsequent events
	During the month of July 2014 the Company entered into 5% one-year promissory notes for a total of $20,000 with arm’s length third parties.
	On August 1, 2014 the Company successfully amended the terms of certain convertible loan agreements with four (4) investors for a total of $125,000 due and payable on November 27, 2015 (ref: Note 6).  Under the amended terms, a total of $125,000 originally available for conversion into a total of 250,000,000 shares of common stock at $0.0005 per share has been amended to reflect a price of $0.005 per share for a total of 25,000,000 shares of common stock, if converted.
	On August 8, 2014 the Company entered into an Agency Agreement (the “Agreement”) with Carter, Terry & Company (“C&T”) where under C&T will act as the Company’s exclusive Financial Advisor, Investment Bank and Placement Agent, on a "best efforts" basis for an initial period of 30 days, and then reverting to a non-exclusive financial advisor for the next twelve consecutive (12) months.  Under the terms of the Agreement, C&T will receive 500,000, fully paid for and earned, restricted shares of the Compnay’s common stock.  In addition, in respect of any introductions that result in financing for the Company C&T shall receive fees as follows:
		a.	10% of the amount for any equity or hybrid equity capital raised up to $2,000,000
		b.	8% of the amount for any equity or hybrid equity capital raised up to $5,000,000
		c.	6% of the amount for any equity or hybrid equity capital raised over $5,000,000
	And;
	an amount of restricted shares equal to 4% of capital raised divided by the closing price of the stock on the date of close.

Correction_of_an_Error_Tables

Correction of an Error (Tables)	6 Months Ended
	Jun. 30, 2014
Correction of an Error [Abstract]
Schedule of originally reported and as adjusted for each major caption of the balance sheet
		31-Dec-13			31-Dec-13
		(As Adjusted)			(Original)
	Consolidated Balance Sheets:
	Derivative liabilities	$	23,790		$	37,614
	Total Liabilities	$	170,954		$	184,778
	Additional paid in capital	$	152,689		$	138,865
	Total stockholders' deficit	$	(130,462	)	$	(144,286	)
	Total liabilities and stockholders' deficit	$	40,492		$	40,492

Fair_Value_Measurements_Tables

Fair Value Measurements (Tables)	6 Months Ended
	Jun. 30, 2014
Fair Value Measurements [Abstract]
Schedule of fair value of derivative liabilities		Fair value measurements
		on a recurring basis
			Level 1		Level 2		Level 3
	As of June 30, 2014:
	Liabilities
	Embedded derivative		$	-	$	-	$	51,708
	As of December 31, 2013:
	Liabilities
	Embedded derivative		$	-	$	-	$	23,790

Share_Purchase_Warrants_Tables

Share Purchase Warrants (Tables)	6 Months Ended
	Jun. 30, 2014
Share Purchase Warrants [Abstract]
Warrants outstanding and exercisable		Warrants		Weighted Average Exercise Price
	Outstanding - December 31, 2013		856,667		0.12
	Granted		93,333		0.3
	Forfeited/Canceled		-		-
	Exercised		-		-
	Outstanding – June 30, 2014		950,000		0.14
	Exercisable – June 30, 2014		950,000		0.14

Derivative_Liabilities_Tables

Derivative Liabilities (Tables)	6 Months Ended
	Jun. 30, 2014
Derivative Liabilities [Abstract]
Schedule of common stock issued and outstanding		169,758,040		Common Stock Issued and Outstanding
		950,000		Common Shares exercised from warrants (950,000 warrants outstanding)
		250,000,000		Common Shares convertible from convertible notes ($125,000 converted at $0.0005 per share )
		62,702,463		Common Shares convertible from Preferred Series A (25,080,985 shares outstanding)
		1,333,333		Common Shares convertible from Preferred Series A warrants (533,333 warrants outstanding)
		484,743,836		Total Common Shares Outstanding and Accounted For/Reserved
Schedule of fair value of derivative liabilities
			Exceed number of authorized shares		Derivate Liabilities
	Balance, December 31, 2013			3,717,169	$	23,790
	Add:  Common shares issued			933,334		10,174
	Common shares for exercise underlying warrants			93,333		1,017
	Change in fair value of derivative liabilities			-		16,727
	Balance: June 30, 2014			4,743,836	$	51,708

Going_Concern_Details

Going Concern (Details) (USD $)	3 Months Ended		6 Months Ended
	Jun. 30, 2014	Jun. 30, 2013	Jun. 30, 2014	Jun. 30, 2013
Going Concern [Abstract]
Net loss	($80,720)	($29,089)	($116,787)	($73,040)

Correction_of_an_Error_Details

Correction of an Error (Details) (USD $)	Jun. 30, 2014	Dec. 31, 2013
Consolidated Balance Sheets:
Derivative liabilities	$51,708	$23,790
Total Liabilities	236,773	170,954
Additional Paid-in Capital	172,475	152,689
Total Stockholders' Deficit	-227,454	-130,462
Total Liabilities and Stockholders' Deficit	9,319	40,492
As Adjusted (Member)
Consolidated Balance Sheets:
Derivative liabilities		23,790
Total Liabilities		170,954
Additional Paid-in Capital		152,689
Total Stockholders' Deficit		-130,462
Total Liabilities and Stockholders' Deficit		40,492
Original (Member)
Consolidated Balance Sheets:
Derivative liabilities		37,614
Total Liabilities		184,778
Additional Paid-in Capital		138,865
Total Stockholders' Deficit		-144,286
Total Liabilities and Stockholders' Deficit		$40,492

Correction_of_an_Error_Details1

Correction of an Error (Details Textual) (USD $)	0 Months Ended
	Dec. 31, 2013
Correction of an Error [Abstract]
Total resulting errors	$13,824

Fair_Value_Measurements_Detail

Fair Value Measurements (Details) (USD $)	Jun. 30, 2014	Dec. 31, 2013
Liabilities
Embedded derivative	$51,708	$23,790
Fair value measurements on a recurring basis Level 1
Liabilities
Embedded derivative
Fair value measurements on a recurring basis Level 2
Liabilities
Embedded derivative
Fair value measurements on a recurring basis Level 3
Liabilities
Embedded derivative	$51,708	$23,790

Loans_Payable_Details

Loans Payable (Details) (USD $)	6 Months Ended
	Jun. 30, 2014	Jun. 30, 2013	Dec. 31, 2013
Loans Payable (Textual)
Loan payable	$63,085		$63,573
Imputed interest	$2,986

Convertible_Notes_Details

Convertible Notes (Details) (USD $)	0 Months Ended		6 Months Ended
	Aug. 01, 2014	Nov. 27, 2012	Jun. 30, 2014	Dec. 31, 2013
Convertible Notes (Textual)
Embedded beneficial conversion feature	$125,000
Carrying values of convertible debenture			33,863	19,190
Convertible Notes [Member]
Convertible Notes (Textual)
Conversion price			$0.00
Convertible Loan Agreements I [Member]
Convertible Notes (Textual)
Interest rate		10.00%
Conversion price		$0.00
Maturity date		27-Nov-15
Face value of convertible debentures		25,000
Embedded beneficial conversion feature		25,000
Convertible debt		25,000
Carrying values of convertible debenture			7,057
Accrued convertible interest			3,973
Convertible Loan Agreements II [Member]
Convertible Notes (Textual)
Interest rate		10.00%
Conversion price		$0.00
Maturity date		27-Nov-15
Face value of convertible debentures		25,000
Embedded beneficial conversion feature		25,000
Convertible debt		25,000
Carrying values of convertible debenture			7,057
Accrued convertible interest			3,973
Convertible Loan Agreement III [Member]
Convertible Notes (Textual)
Interest rate		10.00%
Conversion price		$0.00
Maturity date		27-Nov-15
Face value of convertible debentures		40,000
Embedded beneficial conversion feature		40,000
Convertible debt		40,000
Carrying values of convertible debenture			11,292
Accrued convertible interest			5,337
Convertible Loan Agreement IV [Member]
Convertible Notes (Textual)
Interest rate		10.00%
Conversion price		$0.00
Maturity date		27-Nov-15
Face value of convertible debentures		35,000
Embedded beneficial conversion feature		35,000
Convertible debt		35,000
Carrying values of convertible debenture			8,457
Accrued convertible interest			$5,562

Common_Stock_Details

Common Stock (Details) (USD $)	0 Months Ended	6 Months Ended		0 Months Ended
	Apr. 30, 2014	Jun. 30, 2014	Jun. 30, 2013	Jun. 17, 2013
Common Stock Textual [Abstract]
Proceeds from sale of common stock		$28,000
Installment of a funding agreement	100,000
Funding Agreement [Member]
Common Stock Textual [Abstract]
Proceeds from sale of common stock	28,000
Common stock, shares subscribed	933,333
Share price	$0.03
Exercise price per share	$0.30	$0.30		$0.03
Term of warrant	2 years			2 years
Additional shares of common stock	93,333	93,333
Installment of a funding agreement	$28,000

Share_Purchase_Warrants_Detail

Share Purchase Warrants (Details) (Warrant [Member], USD $)	6 Months Ended
	Jun. 30, 2014
Warrant [Member]
Investment Holdings, Other than Securities [Line Items]
Outstanding begining balance	856,667
Number of warrants granted	93,333
Number of warrants forfeited/canceled
Number of warrants granted exercised
Outstanding ending balance	950,000
Number of warrants exercisable	950,000
Weighted average exercise price begining	$0.12
Weighted average exercise price granted	$0.30
Weighted average exercise price forfeited/canceled
Weighted average exercise price exercised
Weighted average exercise price ending	$0.14
Weighted average exercise price exercisable	$0.14

Share_Purchase_Warrants_Detail1

Share Purchase Warrants (Details Textual) (USD $)	0 Months Ended	6 Months Ended
	Apr. 30, 2014	Jun. 30, 2014	Jun. 17, 2013
Financial Instruments Owned and Pledged as Collateral [Line Items]
Intrinsic value warrants		$0
Funding Agreement [Member]
Financial Instruments Owned and Pledged as Collateral [Line Items]
Additional shares of common stock	93,333	93,333
Exercise price per share	$0.30	$0.30	$0.03
Term of warrant		2 years

Derivative_Liabilities_Details

Derivative Liabilities (Details)	Jun. 30, 2014
Derivative [Line Items]
Common Stock Issued and Outstanding	169,758,040
Total Common Shares Outstanding and Accounted For/Reserved	484,743,836
Warrant [Member]
Derivative [Line Items]
Total Common Shares Outstanding and Accounted For/Reserved	950,000
Convertible Notes [Member]
Derivative [Line Items]
Total Common Shares Outstanding and Accounted For/Reserved	250,000,000
Series A Preferred Stock [Member]
Derivative [Line Items]
Total Common Shares Outstanding and Accounted For/Reserved	62,702,463
Series A Preferred Warrants [Member]
Derivative [Line Items]
Total Common Shares Outstanding and Accounted For/Reserved	1,333,333

Derivative_Liabilities_Details1

Derivative Liabilities (Details 1) (USD $)	6 Months Ended
	Jun. 30, 2014
Exceed Number of Authorized Shares [Member]
Derivative [Line Items]
Begining balance, shares	3,717,169
Add: Common shares issued, shares	933,334
Common shares for exercise underlying warrants, shares	93,333
Ending balance, shares	4,743,836
Derivate Liabilities [Member]
Derivative [Line Items]
Begining balance	23,790
Add: Common shares issued	10,174
Common shares for exercise underlying warrants	1,017
Change in fair value of derivative liabilities	16,727
Ending balance	51,708

Derivative_Liabilities_Details2

Derivative Liabilities (Details Textual) (USD $)	6 Months Ended
	Jun. 30, 2014	Dec. 31, 2013
Derivative Instruments [Textual]
Excess authorized shares of common stock	4,743,836	3,717,168
Common stock, shares authorized	480,000,000	480,000,000
Derivative liability of common stock	$51,708	$23,790
Series A Preferred Stock [Member]
Derivative Instruments [Textual]
Conversion of stock amount converted	25,080,985
Convertible Notes [Member]
Derivative Instruments [Textual]
Conversion of stock amount converted	$125,000
Conversion price	$0.00
Warrant [Member]
Derivative Instruments [Textual]
Warrants outstanding	950,000
Series A Preferred Warrants [Member]
Derivative Instruments [Textual]
Warrants outstanding	533,333

Commitments_Details

Commitments (Details) (USD $)	0 Months Ended		6 Months Ended	0 Months Ended
	Apr. 30, 2014	Jun. 17, 2013	Jun. 30, 2014	Jul. 16, 2013
Funding Agreement [Member]
Commitment (Textual)
Value of shares under funding agreement		$100,000	$100,000
Share price		$0.03
Additional common stock issued during the period, value		100,000
Additional share price	$0.30	$0.03	$0.30
Term of warrant	2 years	2 years
Terms of commitment		Within 90 days (which may be extended by consent of both parties to 120 days)
Second Funding Agreement [Member]
Commitment (Textual)
Value of shares under funding agreement			17,000	17,000
Share price				$0.03
Additional common stock issued during the period, value				$17,000
Additional share price				$0.03
Term of warrant				2 years

Subsequent_Events_Details

Subsequent Events (Details) (Subsequent Event [Member], USD $)	0 Months Ended				1 Months Ended
	Aug. 01, 2014	Aug. 08, 2014			Jul. 31, 2014
	Investors
Subsequent Events (Textual)
Number of investors	4
Convertible debt	$125,000
Conversion of stock amount converted	$125,000
Conversion of stock, shares	250,000,000
Conversion of common stock	25,000,000
Maturity date	27-Nov-15
Conversion price	$0.01
Share price	$0.00
Agency Agreement [Member]
Subsequent Events (Textual)
Restricted shares of common stock		500,000
Subsequent Event, Description		On August 8, 2014 the Company entered into an Agency Agreement (the “Agreement”) with Carter, Terry & Company (“C&T”) where under C&T will act as the Company’s exclusive Financial Advisor, Investment Bank and Placement Agent, on a "best efforts" basis for an initial period of 30 days, and then reverting to a non-exclusive financial advisor for the next twelve consecutive (12) months.  Under the terms of the Agreement, C&T will receive 500,000, fully paid for and earned, restricted shares of the Compnay’s common stock.  In addition, in respect of any introductions that result in financing for the Company C&T shall receive fees as follows:
			a.	10% of the amount for any equity or hybrid equity capital raised up to $2,000,000
			b.	8% of the amount for any equity or hybrid equity capital raised up to $5,000,000
			c.	6% of the amount for any equity or hybrid equity capital raised over $5,000,000
		And;
		an amount of restricted shares equal to 4% of capital raised divided by the closing price of the stock on the date of close.
Related Third Parties [Member]
Subsequent Events (Textual)
Promissory notes interest rate					5.00%
Promissory notes term					1 year